Guide · Updated 2026
Zepbound vs. Mounjaro
Same molecule, same manufacturer, two different labels. The difference is entirely about FDA approval and insurance — not chemistry.
At a glance
| Zepbound | Mounjaro | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| FDA approval | Chronic weight management (BMI ≥30, or ≥27 with comorbidity); OSA in obesity | Type 2 diabetes |
| Manufacturer | Eli Lilly | Eli Lilly |
| Doses available | 2.5, 5, 7.5, 10, 12.5, 15 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| List price (pen) | ~$1,086/mo | ~$1,070/mo |
| Cheapest cash path | LillyDirect vials $349–$499/mo | Manufacturer savings card ($25/mo commercial) |
| Insurance for weight loss | Sometimes covered | Not covered |
| Insurance for diabetes | Not applicable | Widely covered |
Efficacy: identical because it's the same drug
Every study on tirzepatide applies to both. SURMOUNT-1 (Zepbound arm) showed 20.9% average weight loss at 15 mg over 72 weeks. SURPASS-2 (Mounjaro arm) showed A1c reductions of 2.0–2.3% and up to 11.2 kg weight loss in type 2 diabetes. The drug in the pen is chemically indistinguishable.
Why two labels exist
The FDA approves drugs for specific conditions, not molecules. Lilly ran separate trials for diabetes (SURPASS) and obesity (SURMOUNT), got two labels, and packaged them as two products. Insurers rely on FDA labels for coverage decisions, which is why you can't fill a Mounjaro prescription for a weight-loss diagnosis — the label doesn't cover it.
Which one you should ask for
- Type 2 diabetes: Mounjaro. Your insurance will likely cover it.
- Obesity or overweight with a comorbidity: Zepbound. Insurance may cover it; check formulary.
- Paying cash for weight loss: Zepbound vials via LillyDirect ($349–$499/mo).
- Diabetes + no coverage: Mounjaro savings card ($25/mo for commercially insured).
Switching between them
Clinically, no titration reset is needed — a patient on Mounjaro 10 mg who moves to Zepbound 10 mg continues at 10 mg. Practically, you need a new prescription with the matching diagnosis code, and your pharmacy has to have the right pen in stock.
Shortage status
The FDA declared the tirzepatide shortage resolved in late 2024. Compounded tirzepatide is now much harder to obtain legally; most legitimate telehealth providers have shifted patients to brand-name Zepbound or Mounjaro.
FAQ
Are Zepbound and Mounjaro the same drug?
Yes. Both are tirzepatide made by Eli Lilly. Same molecule, same manufacturing, same dose scale — different FDA approval and packaging.
Which is cheaper?
List prices are within about $50/month. Zepbound vials via LillyDirect ($349–$499/mo) are usually the cheapest brand-name path if you're paying cash.
Can I switch between them?
Clinically yes — same drug at the same dose. But your insurance covers one or the other based on your diagnosis, and you need a new prescription.
Which does insurance cover for weight loss?
Only Zepbound. Mounjaro is FDA-approved for type 2 diabetes only, so insurers won't cover it off-label for weight loss.
Do they have the same side effects?
Yes — identical. Nausea, constipation, and fatigue rates match because the drug is identical.
See which providers match your situation
Take a 90-second questionnaire and we'll rank your top 3 telehealth providers by medication, budget, and state availability.
Find My Top 3 MatchesEducational content, not medical advice. Talk to a licensed clinician before starting or changing any medication.